Aura Biosciences, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Aura Biosciences, Inc. (AURA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $6.07 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-11
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.07M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.51M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.97M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7.43M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $6.07M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $6.51M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $6.97M 10-K · filed 2026-03-30 |
| 2025-09-30 | $7.43M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $7.91M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $8.39M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $8.88M 10-K · filed 2025-03-24 |
| 2024-09-30 | $9.38M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $9.89M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $10.40M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.92M 10-K · filed 2024-03-27 |
| 2023-09-30 | $11.47M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $12.00M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $12.54M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $13.09M 10-K · filed 2023-03-15 |
| 2022-09-30 | $13.65M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $12.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $20.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $27.00K 10-K · filed 2022-03-23 |
| 2021-09-30 | $35.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |